300204.SZ深圳证券交易所 · 创业板 ChiNext
Staidson Biopharmaceuticals 舒泰神
Chemical Pharmaceuticals 化学制药
¥20.02−¥0.86 · −4.12%
Open 开盘
¥20.65
High 最高
¥21.18
Low 最低
¥20.01
Prev Close 昨收
¥20.88
Volume 成交量
1,442.7万股
Turnover 成交额
¥2.95亿
Mkt Cap 总市值
¥108亿
P/E 市盈率
−120.6×
Recent Activity 近期动态All Filings 全部公告 →
14 significant filings since 30 May 2026: 8 on share issue, 2 on guarantee or financial assistance and 2 on new listing, and 2 other kinds. The latest, on 21 Sep 2026: 关于公司向银行申请贷款并提供抵押反担保的进展公告（七）. 1 unverified report logged, the latest on 24 Aug 2026.
自 30 May 2026 起有 14 份重大公告：share issue 8 份、guarantee or financial assistance 2 份、new listing 2 份，另有 2 类。最新一份（21 Sep 2026）：关于公司向银行申请贷款并提供抵押反担保的进展公告（七）。记录了 1 条未经核实的报道，最新一条见于 24 Aug 2026。
20.0025.0030.0035.00
Volume 成交量
1.09亿
Sep 25Dec 25Mar 26Jun 26Sep 26
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Chemical Pharmaceuticals 化学制药 · 158 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥108亿 | ¥63亿 | 44th highest of 158 · 158 家中第 44 高 | |
| Trailing P/E 市盈率 | — | 38.6x | No value 无数据 | |
| P/B 市净率 | 11.8x | 2.5x | 13th highest of 157 · 157 家中第 13 高 | |
| Revenue Growth 营收增速 | -26.0% | 1.6% | 9th lowest of 156 · 156 家中第 9 低 | |
| Profit Growth 净利增速 | -49.2% | 1.9% | 23rd lowest of 158 · 158 家中第 23 低 | |
| Gross Margin 毛利率 | 74.1% | 50.2% | 32nd highest of 155 · 155 家中第 32 高 | |
| Net Margin 净利率 | -41.8% | 9.8% | 12th lowest of 157 · 157 家中第 12 低 | |
| Return on Equity 净资产收益率 | -4.5% | 3.1% | 17th lowest of 157 · 157 家中第 17 低 | |
| Debt to Assets 资产负债率 | 39.3% | 28.0% | 53rd highest of 158 · 158 家中第 53 高 | |
| Grade Score 评级得分 | 24 | 51 | 12th lowest of 157 · 157 家中第 12 低 |
Statement figures are for the period to 30 Jun 2026, filed by 158 of 158 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，158 家同业中 158 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Beone Medicines 百济神州 | ¥3,979亿 | 92.9x | 11.2x | 26.8% | 14.7% | 9.9% | B |
| Hengrui Pharma 恒瑞医药 | ¥2,977亿 | 38.5x | 4.6x | -1.9% | 28.9% | 8.0% | C |
| Haisco Pharmaceutical Group 海思科 | ¥699亿 | 73.7x | 14.3x | 54.7% | 27.5% | 18.3% | B |
| CSPC Innovation Pharmaceutical 石药创新 | ¥620亿 | 60.6x | 15.8x | 208.7% | 47.9% | 38.2% | B |
| Sichuan Kelun Pharmaceutical 科伦药业 | ¥618亿 | 33.8x | 2.5x | -2.7% | 16.1% | 4.6% | C |
| Fosun Pharma 复星医药 | ¥610亿 | 18.0x | 1.3x | 4.8% | 10.5% | 3.5% | D |
| Innocare 诺诚健华 | ¥528亿 | 57.5x | 6.9x | 55.5% | 21.1% | 3.2% | C |
| Allist 艾力斯 | ¥469亿 | 17.5x | 5.5x | 39.9% | 46.4% | 19.7% | B |
| Huadong Medicine 华东医药 | ¥457亿 | 13.2x | 1.8x | 1.8% | 8.3% | 7.3% | C |
| Shenzhen Salubris Pharmaceuticals 信立泰 | ¥337亿 | 50.0x | 3.9x | 16.3% | 15.8% | 4.3% | C |
| Humanwell Healthcare ST人福 | ¥307亿 | 15.1x | 1.6x | -0.0% | 14.0% | 6.8% | C |
| Apeloa Pharmaceutical 普洛药业 | ¥293亿 | 34.5x | 4.5x | -11.4% | 10.8% | 8.1% | D |
| Zelgen 泽璟制药 | ¥288亿 | 52.5x | 16.8x | 220.9% | 53.1% | 45.7% | B |
| Dizal Pharmaceutical 迪哲医药 | ¥263亿 | — | 23.2x | 47.2% | -40.8% | -17.2% | D |
| Staidson Biopharmaceuticals 舒泰神 | ¥108亿 | — | 11.8x | -26.0% | -41.8% | -4.5% | E |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。